Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12142)
All Articles published online
|
Publishing Process of This Article
|
Jun 28, 2015 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bhat A, Sebastiani G, Bhat M. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol 2015; 7(12): 1652-1659 [PMID: 26140084 DOI: 10.4254/wjh.v7.i12.1652] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v7/i12/1652.htm |
| Number | Citing Articles |
| 1 |
Lu Cai, Kai Hu, Ling Lin, Qing Ai, Pu Ge, Yiqing Liu, Jie Dai, Bin Ye, Li Zhang. AMPK dependent protective effects of metformin on tumor necrosis factor-induced apoptotic liver injury. Biochemical and Biophysical Research Communications 2015; 465(3): 381 doi: 10.1016/j.bbrc.2015.08.009
|
| 2 |
Laura Iogna Prat, Emmanuel A. Tsochatzis. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones 2018; 17(2): 219 doi: 10.1007/s42000-018-0021-9
|
| 3 |
|
| 4 |
Zhe Zheng, Yue Li, Siyuan Fan, Jie An, Xi Luo, Minglu Liang, Feng Zhu, Kai Huang. WW domain-binding protein 2 overexpression prevents diet-induced liver steatosis and insulin resistance through AMPKβ1. Cell Death & Disease 2021; 12(3) doi: 10.1038/s41419-021-03536-8
|
| 5 |
Rong Shi, Xining Xu, Jiasheng Wu, Tianming Wang, Yuanyuan Li, Bingliang Ma, Yueming Ma. Hydrophilic interaction chromatography-tandem mass spectrometry based on an amide column for the high-throughput quantification of metformin in rat plasma. RSC Advances 2015; 5(123): 101386 doi: 10.1039/C5RA20500J
|
| 6 |
Wei Wu, Jun-Ling Yang, Yi-Lang Wang, Han Wang, Min Yao, Li Wang, Juan-Juan Gu, Yin Cai, Yun Shi, Deng-Fu Yao. Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting <i>NF-κB</i> gene transcription. World Journal of Hepatology 2016; 8(23): 985-993 doi: 10.4254/wjh.v8.i23.985
|
| 7 |
Rejane Augusta de Oliveira Figueiredo, Elisabete Weiderpass, Eloiza Helena Tajara, Peter Ström, André Lopes Carvalho, Marcos Brasilino de Carvalho, Jossi Ledo Kanda, Raquel Ajub Moyses, Victor Wünsch-Filho. Diabetes mellitus, metformin and head and neck cancer. Oral Oncology 2016; 61: 47 doi: 10.1016/j.oraloncology.2016.08.006
|
| 8 |
Xu Li, Hongqin Xu, Yang Gao, Meng Pan, Le Wang, Pujun Gao. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine 2017; 96(13): e6508 doi: 10.1097/MD.0000000000006508
|
| 9 |
Chenggui Miao, Zhongwen Xie, Jun Chang. Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions. Biochemical Genetics 2018; 56(5): 423 doi: 10.1007/s10528-018-9870-9
|
| 10 |
Daniela Maria Tanase, Evelina Maria Gosav, Claudia Florida Costea, Manuela Ciocoiu, Cristina Mihaela Lacatusu, Minela Aida Maranduca, Anca Ouatu, Mariana Floria. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Diabetes Research 2020; 2020: 1 doi: 10.1155/2020/3920196
|
| 11 |
Ans Jacobs, Anne‐Sophie Warda, Jef Verbeek, David Cassiman, Pieter Spincemaille. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. Current Protocols in Mouse Biology 2016; 6(2): 185 doi: 10.1002/cpmo.3
|
| 12 |
Ashwini Arvind, Zoe N. Memel, Lisa L. Philpotts, Hui Zheng, Kathleen E. Corey, Tracey G. Simon. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis. Metabolism 2021; 120: 154780 doi: 10.1016/j.metabol.2021.154780
|
| 13 |
Stephen Safe, Vijayalekshmi Nair, Keshav Karki. Metformin-induced anticancer activities: recent insights. Biological Chemistry 2018; 399(4): 321 doi: 10.1515/hsz-2017-0271
|
| 14 |
Soraya J Kaewpitoon, Ryan A Loyd, Ratana Rujirakul, Sukij Panpimanmas, Likit Matrakool, Taweesak Tongtawee, Nusorn Kootanavanichpong, Ponthip Kompor, Wasugree Chavengkun, Jirawoot Kujapun, Jun Norkaew, Sukanya Ponphimai, Natnapa Padchasuwan, Poowadol Pholsripradit, Thawatchai Eksanti, Tanida Phatisena, Natthawut Kaewpitoon. Benefits of Metformin Use for Cholangiocarcinoma. Asian Pacific Journal of Cancer Prevention 2016; 16(18): 8079 doi: 10.7314/APJCP.2015.16.18.8079
|
| 15 |
Betül Evran, Abdurrahman Fatih Aydın, Buse Uğuralp, Mehmet Sar, Semra Doğru-Abbasoğlu, Müjdat Uysal. Betaine treatment decreased serum glucose and lipid levels, hepatic and renal oxidative stress in streptozotocin-induced diabetic rats. Turkish Journal of Biochemistry 2018; 43(4): 343 doi: 10.1515/tjb-2016-0183
|
| 16 |
Marco Sacco, Davide Giuseppe Ribaldone, Giorgio Maria Saracco. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?. Viruses 2023; 15(12): 2451 doi: 10.3390/v15122451
|
| 17 |
Narges Hedayati, Zahra Oskouei, Jamshid Tabeshpour, Mehri Bemani Naeini. Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review. European Journal of Pharmacology 2021; 913: 174590 doi: 10.1016/j.ejphar.2021.174590
|
| 18 |
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran. Non-alcoholic Fatty Liver Disease: A Clinical Update. Journal of Clinical and Translational Hepatology 2017; (XX): XX doi: 10.14218/JCTH.2017.00013
|
| 19 |
Brennan K. Smith, Katarina Marcinko, Eric M. Desjardins, James S. Lally, Rebecca J. Ford, Gregory R. Steinberg. Treatment of nonalcoholic fatty liver disease: role of AMPK. American Journal of Physiology-Endocrinology and Metabolism 2016; 311(4): E730 doi: 10.1152/ajpendo.00225.2016
|
| 20 |
Mohammed Alqarni, Abdullah A. Alshehri, Hassan Arida, Mahmood Ahmed. Validation and Application of Screen-Printed Microchip for Potentiometric Determination of Metformin Hydrochloride in Tablet Dosage Form. International Journal of Analytical Chemistry 2024; 2024: 1 doi: 10.1155/2024/8664723
|
| 21 |
Felix Gundling. Der hepatogene Diabetes – aktueller Stand der Diagnostik und Therapie. Journal für Klinische Endokrinologie und Stoffwechsel 2022; 15(2): 42 doi: 10.1007/s41969-022-00158-z
|
| 22 |
Kuo Du, Anup Ramachandran, James L. Weemhoff, Hemantkumar Chavan, Yuchao Xie, Partha Krishnamurthy, Hartmut Jaeschke. Editor’s Highlight: Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction. Toxicological Sciences 2016; 154(2): 214 doi: 10.1093/toxsci/kfw158
|
| 23 |
Ulfa Kholili, Alvin Hartanto Kurniawan, Choirina Winda, Ummi Maimunah, Poernomo Budi Setiawan. The Role of Metformin as Chemopreventive Strategies for Hepatocellular Carcinoma. Research Journal of Pharmacy and Technology 2023; : 377 doi: 10.52711/0974-360X.2023.00065
|
| 24 |
Xue Yu, Yan Wang, Jianming Lai, Ting Song, Jianping Duan. Comparative efficacy of exercise training processes in improving nonalcoholic fatty liver disease: a systematic review and meta-analysis. Irish Journal of Medical Science (1971 -) 2023; 192(1): 131 doi: 10.1007/s11845-022-02988-x
|
| 25 |
T. Yu. Demidova, M. Ya. Izmailova, K. M. Belova, V. V. Titova. New prospects for the interdisciplinary use of metformin in clinical practice: its role in the treatment of non-alcoholic fatty liver disease. FOCUS. Endocrinology 2023; 4(3): 41 doi: 10.15829/2713-0177-2023-3-14
|
| 26 |
Yoshihito Fujita, Nobuya Inagaki. Metformin: New Preparations and Nonglycemic Benefits. Current Diabetes Reports 2017; 17(1) doi: 10.1007/s11892-017-0829-8
|
| 27 |
André J. Scheen. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD). Diabetes Epidemiology and Management 2023; 11: 100145 doi: 10.1016/j.deman.2023.100145
|
| 28 |
Abdulrahman Ismaiel, Dan L. Dumitrascu. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. American Journal of Therapeutics 2023; 30(3): e242 doi: 10.1097/MJT.0000000000001174
|
| 29 |
Preetam Nath, Anil C. Anand. Hepatogenous Diabetes: A Primer. Journal of Clinical and Experimental Hepatology 2021; 11(5): 603 doi: 10.1016/j.jceh.2021.04.012
|
| 30 |
John Vizuete, Alfredo Camero, Mazyar Malakouti, Karthik Garapati, Julio Gutierrez. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. Journal of Clinical and Translational Hepatology 2017; 5(1): 67 doi: 10.14218/JCTH.2016.00061
|
| 31 |
Jonggi Choi, Lewis R. Roberts. Statins and metformin for chemoprevention of hepatocellular carcinoma. Clinical Liver Disease 2016; 8(2): 48 doi: 10.1002/cld.568
|
| 32 |
Xiaoyan Xu, Yaqin Sun, Xufeng Cen, Bing Shan, Qingwei Zhao, Tingxue Xie, Zhe Wang, Tingjun Hou, Yu Xue, Mengmeng Zhang, Di Peng, Qiming Sun, Cong Yi, Ayaz Najafov, Hongguang Xia. Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model. Protein & Cell 2021; 12(10): 769 doi: 10.1007/s13238-021-00858-3
|
| 33 |
Shalini Sivadasan, Muthukumar Subramanian, Rajasekaran Aiyalu. Metformin - Pharmacology and Drug Interactions. 2021; doi: 10.5772/intechopen.99815
|
| 34 |
Antje Garten, Susanne Schuster, Melanie Penke. Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma?. Expert Review of Anticancer Therapy 2017; 17(4): 289 doi: 10.1080/14737140.2017.1298447
|
| 35 |
Niloofar Haghdadi, Sakineh Asghari, Ghasem Firouzzadeh Pasha. Synthesis and characterization of functionalized nano NaY zeolite with metformin and use for the synthesis of 2-amino-4H-chromenes. Research on Chemical Intermediates 2024; 50(5): 1961 doi: 10.1007/s11164-024-05258-w
|
| 36 |
Fu-Shun Yen, Chih-Cheng Hsu, James Cheng-Chung Wei, Ming-Chih Hou, Chii-Min Hwu. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.839456
|
| 37 |
Anna Simona Sasdelli, Lucia Brodosi, Giulio Marchesini. NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Current Hepatology Reports 2016; 15(2): 103 doi: 10.1007/s11901-016-0297-7
|
| 38 |
Raul D. Santos, Luca Valenti, Stefano Romeo. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019; 282: 110 doi: 10.1016/j.atherosclerosis.2019.01.029
|
| 39 |
Lena Schulte, Bernhard Scheiner, Torsten Voigtländer, Sandra Koch, Nora Schweitzer, Silke Marhenke, Philipp Ivanyi, Michael P. Manns, Thomas Rodt, Jan B. Hinrichs, Arndt Weinmann, Matthias Pinter, Arndt Vogel, Martha M. Kirstein. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver International 2019; 39(4): 714 doi: 10.1111/liv.14048
|
| 40 |
Roberto Romero, Offer Erez, Maik Hüttemann, Eli Maymon, Bogdan Panaitescu, Agustin Conde-Agudelo, Percy Pacora, Bo Hyun Yoon, Lawrence I. Grossman. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. American Journal of Obstetrics and Gynecology 2017; 217(3): 282 doi: 10.1016/j.ajog.2017.06.003
|
| 41 |
Thanida Tangjarusritaratorn, Watip Tangjittipokin, Tada Kunavisarut. Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 1563 doi: 10.2147/DMSO.S295753
|
| 42 |
L. Yu. Morgunov. DIABETES MELLITUS IN PATIENTS WITH LIVER CIRRHOSIS: NEW TREATMENT OPTIONS. Research'n Practical Medicine Journal 2017; 4(3): 75 doi: 10.17709/2409-2231-2017-4-3-7
|
| 43 |
Yun‐Shan Wang, Lutao Du, Xingsi Liang, Peng Meng, Lei Bi, Yu‐li Wang, Chuanxin Wang, Bo Tang. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine‐Monophosphate–Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. Hepatology 2019; 69(4): 1614 doi: 10.1002/hep.30421
|
| 44 |
Yuansheng Liu, Qian Zhang, Lei Yang, Wencong Tian, Yinan Yang, Yuhang Xie, Jing Li, Liang Yang, Yang Gao, Yang Xu, Jie Liu, Yachen Wang, Jie Yan, Guoxun Li, Yanna Shen, Zhi Qi. Metformin Attenuates Cardiac Hypertrophy Via the HIF-1α/PPAR-γ Signaling Pathway in High-Fat Diet Rats. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.919202
|
| 45 |
Chaofu Li, Yating Deng, Yating Pan, Xinyi Liao, Huadong Xie, Xiaoli Xue, Shaoqing Yu, Wenlong Yu, Guanzhen Yu. Metformin dampens the progression of cholangiofibrosis induced by thioacetamide using deep learning. Heliyon 2024; 10(18): e37347 doi: 10.1016/j.heliyon.2024.e37347
|
| 46 |
Deepika Kathuria, Akshay D. Raul, Pravin Wanjari, Prasad V. Bharatam. Biguanides: Species with versatile therapeutic applications. European Journal of Medicinal Chemistry 2021; 219: 113378 doi: 10.1016/j.ejmech.2021.113378
|
| 47 |
Maria Corina Plaz, Emmanuel A. Tsochatzis. Textbook of Liver Transplantation. 2022; : 357 doi: 10.1007/978-3-030-82930-8_20
|
| 48 |
Rebekka Pohl, Elisabeth M. Haberl, Lisa Rein‐Fischboeck, Sebastian Zimny, Maximilian Neumann, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Kristina Eisinger, Thomas S. Weiss, Christa Buechler. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. European Journal of Clinical Investigation 2017; 47(1): 7 doi: 10.1111/eci.12695
|
| 49 |
Everton Cazzo, José Carlos Pareja, Elinton Adami Chaim. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Medical Journal 2017; 135(3): 277 doi: 10.1590/1516-3180.2016.0306311216
|
| 50 |
Abdulrahman Ismaiel, Dan L. Dumitraşcu. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review. Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00202
|
| 51 |
Z A Kalmykova, I V Kononenko, A Yu Mayorov. Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features. Terapevticheskii arkhiv 2019; 91(12): 115 doi: 10.26442/00403660.2019.12.000166
|
| 52 |
Andrea Boccatonda, Damiano D’Ardes, Veronica Moronti, Jessica Santilli, Alessia Cipollone, Gianfranco Lessiani, Nicoletta Di Gregorio, Carla Serra, Fabio Piscaglia, Claudio Ferri, Francesco Cipollone. From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status. Medicina 2024; 60(11): 1781 doi: 10.3390/medicina60111781
|
| 53 |
Mehrnaz Abbasi, Braeden Heath, Lauren McGinness. Advances in metformin‐delivery systems for diabetes and obesity management. Diabetes, Obesity and Metabolism 2024; 26(9): 3513 doi: 10.1111/dom.15759
|
| 54 |
Catalina Mihai, Bogdan Mihai, Cristina Cijevschi Prelipcean. Essentials of Non-Alcoholic Fatty Liver Disease. 2023; : 159 doi: 10.1007/978-3-031-33548-8_14
|
| 55 |
Diego García-Compeán, Emanuela Orsi, Ramesh Kumar, Felix Gundling, Tsutomu Nishida, Jesús Zacarías Villarreal-Pérez, Ángel N Del Cueto-Aguilera, José A González-González, Giuseppe Pugliese. Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World Journal of Gastroenterology 2022; 28(8): 775-793 doi: 10.3748/wjg.v28.i8.775
|
| 56 |
André J. Scheen. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update. Expert Opinion on Drug Metabolism & Toxicology 2023; 19(8): 543 doi: 10.1080/17425255.2023.2252333
|
| 57 |
Laura Belloni, Silvia Di Cocco, Francesca Guerrieri, Abigail D. G. Nunn, Silvia Piconese, Debora Salerno, Barbara Testoni, Claudio Pulito, Federica Mori, Matteo Pallocca, Andrea Sacconi, Elisa Vivoli, Fabio Marra, Sabrina Strano, Giovanni Blandino, Massimo Levrero, Natalia Pediconi. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-31835-2
|
| 58 |
Paola Dongiovanni, Raffaela Rametta, Marica Meroni, Luca Valenti. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?. Expert Review of Gastroenterology & Hepatology 2016; 10(2): 229 doi: 10.1586/17474124.2016.1110018
|
| 59 |
Jinqing Wu, Yabo Zhou, Guizhou Wang, Nicola Silvestris. Metformin Use and Survival in Patients with Advanced Extrahepatic Cholangiocarcinoma: A Single-Center Cohort Study in Fuyang, China. Gastroenterology Research and Practice 2021; 2021: 1 doi: 10.1155/2021/9468227
|
| 60 |
Atsushi Sawamoto, Madoka Okada, Nanako Matsuoka, Satoshi Okuyama, Mitsunari Nakajima. Tipepidine activates AMPK and improves adipose tissue fibrosis and glucose intolerance in high‐fat diet‐induced obese mice. The FASEB Journal 2024; 38(5) doi: 10.1096/fj.202301861RR
|
| 61 |
Sofia de Oliveira, Ruth A. Houseright, Alyssa L. Graves, Netta Golenberg, Benjamin G. Korte, Veronika Miskolci, Anna Huttenlocher. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. Journal of Hepatology 2019; 70(4): 710 doi: 10.1016/j.jhep.2018.11.034
|
| 62 |
Ziquan Lv, Yajie Guo. Metformin and Its Benefits for Various Diseases. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.00191
|